Generic placeholder image

Current Vascular Pharmacology


ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies

Author(s): Shin-ichi Satoh, Ichiro Ikegaki, Koh Kawasaki, Toshio Asano and Masato Shibuya

Volume 12, Issue 5, 2014

Page: [758 - 765] Pages: 8

DOI: 10.2174/1570161112666140613115813

Price: $65


There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH). A number of pathological processes, in particular hemodynamic dysfunctions and inflammatory reactions, are thought to be related in the pathogenesis of delayed cerebral vasospasm and subsequent ischemic injury after SAH. This review focuses on fasudil’s pleiotropic therapeutic effects: amelioration of hemodynamic dysfunction and inflammation, and discusses in detail the clinical studies on fasudil administered after the occurrence of SAH.

Keywords: Cerebral vasospasm, fasudil, hydroxyfasudil, pleiotropic therapeutic effects, Rho-kinase, subarachnoid hemorrhage.

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy